Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD.

about

Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies.

P2860

Q38637363-1FD1BB16-CACA-45B4-8869-4D5C90B36F41

P2860

Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD.

Item

http://www.wikidata.org/entity/Q43110445

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD.

@en

Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD.

@nl

type

Item

label

Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD.

@en

Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD.

@nl

prefLabel

Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD.

@en

Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD.

@nl

P1476

Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD.

@en

P2093

W H Wilson Tang

http://www.w3.org/2001/XMLSchema#string

P2860

Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk

Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis

Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation

Antibiotics and the gut microbiota.

Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease

Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure

The gut microbiome, kidney disease, and targeted interventions.

The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction.

Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide

P304

8-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1681/ASN.2015050576

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26229138

http://www.w3.org/2001/XMLSchema#string

P932

4696591

http://www.w3.org/2001/XMLSchema#string

Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD.

about

P2860

P2860

Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932